Double Transgenic APPxPS1 Mouse Models – ARTE10 mouse model

The ARTE10 mouse model is particularly well-suited for proof-of-concept and early efficacy studies targeting amyloid-beta pathology. Due to its robust and progressive plaque deposition, ARTE10 is frequently used to evaluate anti-amyloid antibodies, BACE inhibitors, γ-secretase modulators, aggregation inhibitors, and plaque-clearing immunotherapies. Because amyloid plaque burden is abundant and reproducible, ARTE10 allows clear quantification of treatment effects on amyloid load. 

Although literature reports that ARTE10 mice may develop mild cognitive alterations around 12 months of age, particularly affecting episodic memory, the behavioral phenotype is less pronounced compared to other models.  

For programs where cognitive improvement is a primary endpoint, InnoSer’s APP[V717I]xPS1[A246E] mouse model may offer greater sensitivity, as this model demonstrates clear spatial memory deficits in the Morris water maze along with documented compound-mediated rescue effects (see also figures 1 and 2 of Easton et al., 2013). 

For therapies targeting Tau pathology, tau phosphorylation, neurofibrillary tangle formation, or combined amyloid-and-Tau disease modification, we recommend the APP[V717I]xTau[P301S] mouse model, which recapitulates both extracellular amyloid plaques and progressive Tau pathology, providing a more complete Alzheimer’s disease phenotype. 

Not sure which model best fits your therapeutic strategy? We’re happy to discuss your mechanism of action, endpoints, and study timeline to recommend the most translationally relevant model for your program.

InnoSer applies standardized, semi-automated image analysis workflows to quantify amyloid plaque load in a reproducible and region-specific manner. Methoxy-X04 staining and immunohistochemistry (e.g., 6E10) are used to assess plaque number, size distribution, and total plaque burden across defined brain regions. This quantitative approach enables sensitive detection of treatment-induced changes in amyloid pathology. 

Reach out to our expert scientific team to learn more about how your therapeutic evaluation can be sped up.

Yes, the ARTE10 model has demonstrated pharmacodynamic responsiveness to amyloid-lowering interventions. For example, the original publication characterizing the mouse model (Willuweit et al., 2007) has demonstrated that treatment with the γ-secretase inhibitor MRK-560 (compound 32) significantly reduced soluble Aβ40 and Aβ42 levels in the brain following acute oral dosing. Soluble Aβ40 and Aβ42 levels were reduced in a dose-dependent manner by up to 72% and 27%, respectively, confirming that amyloid production can be effectively modulated in this model. 

These findings support the suitability of the ARTE10 mouse model for assessing target engagement and efficacy of compounds designed to reduce Aβ production or enhance clearance.

Yes, with advancing plaque pathology, ARTE10 mice aged 19 months develop cerebral amyloid angiopathy (CAA) characterized by the accumulation of Aβ within intracortical, leptomeningeal, and choroidal blood vessels (Willuweit et al., 2007). 

Cerebral amyloid angiopathy (CAA) is a common and clinically relevant cerebrovascular pathology characterized by the accumulation of Aβ peptides within the walls of cerebral blood vessels. CAA is present in a substantial proportion of Alzheimer’s disease patients and is increasingly recognized as a key contributor to vascular dysfunction, impaired cerebral blood flow, blood–brain barrier disruption, and intracerebral haemorrhage.  

In recent years, interest in CAA has grown markedly as clinical trial outcomes have highlighted vascular amyloid as a potential driver of treatment-related adverse events, including amyloid-related imaging abnormalities (ARIA). Consequently, CAA has emerged as an important target for mechanistic studies and for the preclinical evaluation of anti-amyloid therapies, particularly immunotherapies and approaches aimed at improving vascular amyloid clearance. 

Although the ARTE10 mouse model recapitulates late-stage vascular amyloid deposition, the onset in pathology development has been reported at 19 months of age. Therefore, for programs specifically investigating earlier-onset CAA or microbleeds, InnoSer’s APP[V717I]xPS1[A246E] mouse model may offer strategic advantages. In this model, cerebral amyloid angiopathy develops earlier (from approximately 8 months of age), and microbleeds may occur at later stages (around 12–15 months), providing a broader experimental window for evaluating vascular safety, ARIA-related mechanisms, and cerebrovascular liability of anti-amyloid therapies. 

Reach out to our team to explore how InnoSer can support the preclinical assessment of cerebral amyloid angiopathy (CAA) and amyloid-related imaging abnormalities (ARIA).